| Title
of the article |
Oral valganciclovir is noninferior to intravenous ganciclovir for the treatment of cytomegalovirus disease in solid organ transplant recipients. |
| Authors |
Asberg A, Humar A, Rollag H, Jardine AG, Mouas H, Pescovitz MD, Sgarabotto D, Tuncer M, Noronha IL, Hartmann A; on behalf of the VICTOR Study Group. |
| Journal
|
Am J Transplant. 2007 Sep;7(9):2106-13. Epub 2007 Jul 19. |
| Subject
Consultant |
B. Watschinger |
| Score
(1 to 3 stars) |
*** |
| Comments |
In this randomized trial, in which recipients with cytomegalovirus disease were treated with either oral valganciclovir [n = 164] or i.v. ganciclovir [n = 157] efficacy and safety was comparable. |
